AG (Intercell) is an Austria-based biotechnology company that focuses on
the development and manufacturing of vaccines and monoclonal antibodies
for the prevention and treatment of infectious diseases. The Company’s
technology platforms include an antigen-discovery system, adjuvants and
a patch-based delivery system. Intercell’s portfolio consists of one marketed
product, eight product candidates in clinical development and additional
candidates in pre-clinical development. Its core product is a Japanese
Encephalitis vaccine. The focus of the development portfolio of the Company
is on nosocomial infections and other selected serious infectious diseases.
Its development pipeline includes a Staphylococcus aureus vaccine (P hase
II/III); Pseudomonas vaccine (Phase II), and a Pandemic Influenza patch
system (Phase I/II), among others. Intercell operates in Austria, Scotland
and the United States. It has partnerships with Merck & Co., Novartis,
GlaxoSmithKline and sanofi-aventis.
Vienna Biocenter 2